Leading enterprise intelligence software provider SAS has signed a global licensing agreement worth US$9 million over three years with pharmaceutical giant AstraZeneca. The agreement reflects AstraZeneca's recognition of SAS as one of a small number of IT suppliers identified as being able to help AstraZeneca meet its strategic goals.
"We will use SAS enterprise intelligence in business projects that contribute towards two of our key shareholder value goals of becoming a faster and more efficient organisation and growing through new products," says Johnson Idesoh, Head of Development Information Systems at AstraZeneca. "We see this agreement as a first step in building a strategic relationship between our two companies."
SAS software is currently used by AstraZeneca in 24 countries, primarily in the area of clinical research and development (R&D). The new license presents the opportunity for expansion of AstraZeneca's usage of the software both within R&D in areas such as drug portfolio management (identifying compounds that are most likely to become marketable drugs) and in new areas such as strategic performance management (monitoring whether the company is meeting its key business targets) as well as in sales and marketing.
"SAS has both the completeness of solution-set and the coherence of vision to help us meet our need for generating and sharing intelligence across the entire organisation, bridging the divides between different sources of data, different departments and different geographies," says Idesoh. "The use of SAS gives us the ability to access data from a variety of sources, analyse it and draw conclusions within one environment. This power is critical in improving our efficiency. On a number of drug projects we have experience of rapidly consolidating information, often from as many as 24 different countries, within a few hours using SAS. We also see opportunities to use technologies like data mining in the rapid identification of promising new medicines. SAS' ability to meet a diverse range of intelligence needs, ranging from our core business of drug discovery and development, to more generalised business applications, was a definitive criteria in our decision to build a strate!
gic relationship between our two companies."
"AstraZeneca is one of a number of forward-looking corporations that recognise that an integrated approach to generating and sharing intelligence throughout the organisation can impact directly and positively on that organisation's ability to meet its promises to shareholders," says President of SAS International, Art Cooke.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $16.4 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products.
SAS is the market leader in providing a new generation of business intelligence software and services that create true enterprise intelligence. SAS solutions are used at more than 38,000 sites - including 99 of Fortune 100 businesses - to develop more profitable relationships with their customers and suppliers, to make better, more accurate and informed decisions, and to drive their organisations forward. SAS is the only vendor that completely integrates leading data warehousing, analytics, and traditional BI applications to create intelligence from massive amounts of data. For 25 years, SAS has been giving customers around the world The Power to Know(tm).
For further information, please contact the team at the SAS press office on:
Tel: +44 (0) 20 7841 5738, fax:+44 (0)20 7240 1910 or e-mail
For more information on SAS, please visit http://www.sas.com/uk
SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. (r) indicates USA registration. Other brand and product names are trademarks of their respective companies. Copyright (c) 2002 SAS Institute
This press release was distributed by ResponseSource Press Release Wire on behalf of Golin in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.